It has been argued that salvinorin A is an atypical KOR agonist, with a complex pharmacological profile, influencing dopaminergic, glutamatergic and cannabinoid systems, and should be examined as a potential treatment for depression (Taylor and Manzella, 2016). This evidence concerns the gene OPRK1 and depressive disorder.